Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Shanghai"

50 News Found

Evonik opens new medical device center in Shanghai
News | July 12, 2025

Evonik opens new medical device center in Shanghai

The company’s largest center for medical device applications, serving the entire Asian market


IMCD opens life science laboratory hub in Shanghai
News | July 09, 2025

IMCD opens life science laboratory hub in Shanghai

The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms


Carbogen Amcis (Shanghai) completed ANVISA Audit
Drug Approval | March 19, 2024

Carbogen Amcis (Shanghai) completed ANVISA Audit

A five-day inspection was concluded successfully with no critical and no major observations raised


Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


GenSci launches global innovation hub in Shanghai
News | December 26, 2023

GenSci launches global innovation hub in Shanghai

The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges


Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China
News | April 19, 2023

Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China

Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China


WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services
Biotech | October 22, 2021

WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services

It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China


Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
Drug Approval | September 15, 2025

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis


Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day
News | July 08, 2025

Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day

The company showcased three core programs developed through this platform